Ai

Aimmune

Brisbane CAFounded 2011300 employees
Private CapbiotechAcquiredImmunology
Platform: Palforzia
Market Cap
N/A
All Drugs
3
Clinical Trials
7
Failed / Terminated
2
FDA Approved
1
Drug Pipeline (3 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
OlpaosocimabAIM-7223Approved4siRNASGLT2KRASG12DiRSV
NidacilimabAIM-8330Preclinical1VaccineJAK1C5iLGSDMD
AIM-9920AIM-9920Phase 22PeptideAuroraACDK2iT2DMM
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (5)
2026-01-22
Olpaosocimab Ph3 Readout
RSV
Past
2030-10-14
AIM-9920 Ph2 Data
T2D
Ph2 Data
2030-10-15
Olpaosocimab Ph3 Readout
RSV
Ph3 Readout
2031-01-25
AIM-9920 Ph2 Data
Huntington's
Ph2 Data
2031-07-18
Nidacilimab Interim
DMD
Interim